3D Medicines

develops companion diagnostics and genomic testing paired with domestic and global oncology drug approvals, part of China's growing precision-oncology testing base.

Country: China

Commercial Companion diagnostics & genomic testing

Coverage

	CN	EU	IN	US
diagnostics-medtech	✓	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	$140 million (approx. RMB 970 million) Series A for 3D Medicines Inc. diagnostics business unit (2020-10-08)	en.3d-medicines.com · vcbeathealth.com
Capacity	2000L production scale for Envafolimab Injection approved by NMPA (2024-07-03)	ir.3d-medicines.com · www1.hkexnews.hk
Certification	third-party medical test centers with dual CAP/CLIA accreditation (2021-01-01)	3dmedcare.com
Regulatory approval	NMPA accepted supplemental application for Envafolimab to transition from conditional to regular approval (2026-02-09)	ir.3d-medicines.com · www1.hkexnews.hk
Regulatory approval	Class III in-vitro diagnostic approval for OncoMate Microsatellite Instability Detection Kit (2026-03-05)	ir.3d-medicines.com · prnewswire.com · www1.hkexnews.hk
Production site	Xuzhou, Jiangsu province (under construction) (2026-03-31)	ir.3d-medicines.com · www1.hkexnews.hk
Headcount	more than 1100 employees (2021-01-01)	3dmedcare.com
Revenue	RMB 356.1 million for 2025 (2025-12-31)	ir.3d-medicines.com · www1.hkexnews.hk

Independent sources: 3dmedcare.com · prnewswire.com · vcbeathealth.com · www1.hkexnews.hk

Technologies

Name	Cluster	Risk
Companion diagnostics platforms	diagnostics-medtech	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.